BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2019
Bergen, Norway, 11 February 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2019. A presentation and live webcast by the Company’s management will take place today at 10.00 am CET in Oslo, please see below for details. Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “I am pleased to report on another eventful quarter for BerGenBio. During the period bemcentinib was approved for Fast Track